Mayukh Sukhatme is a seasoned finance executive serving as President and Chief Investment Officer at Roivant Sciences Ltd., a innovative biopharmaceutical company focused on developing transformative medicines. In this pivotal role, he oversees the company's investment strategy, capital allocation, and financial operations, guiding Roivant's portfolio of "Vants" – specialized subsidiaries targeting unmet medical needs across various therapeutic areas. Sukhatme's leadership has been instrumental in driving Roivant's growth, including strategic partnerships, acquisitions, and the successful navigation of complex market dynamics in the biotech sector. His expertise in identifying high-potential opportunities has helped position Roivant as a leader in accelerating drug development and commercialization, ultimately aiming to deliver life-changing therapies to patients worldwide. Prior to joining Roivant in 2015, Sukhatme built an impressive career in investment management, beginning at prestigious firms such as Citadel LLC, where he managed global healthcare investments and honed his skills in equity research and portfolio management. He previously held roles at Surveyor Capital and other hedge funds, where he demonstrated a keen ability to analyze market trends and generate alpha in volatile sectors. Sukhatme's academic foundation includes a bachelor's degree in economics from the University of Pennsylvania's Wharton School, providing him with a strong analytical framework that has underpinned his professional success. Throughout his career, he has been recognized for his strategic acumen, contributing to significant value creation for investors and stakeholders. Under Sukhatme's stewardship, Roivant has achieved notable milestones, including the launch of multiple clinical-stage programs and the expansion of its pipeline through innovative deal-making. His forward-thinking approach has facilitated key transactions, such as collaborations with major pharmaceutical players, enhancing Roivant's ability to bring novel treatments to market efficiently. As the biotech landscape evolves, Sukhatme continues to champion data-driven decision-making and sustainable growth, positioning Roivant for long-term success in an industry ripe with opportunity and challenge.